Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma(INZY) Newsfilter·2024-08-06 20:30- Complete enrollment in ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected third quarter of 2024 - - Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Interim data from SEAPORT 1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 – - Cash, cash equivalents, and short-term investments as of June 30, 2024, expect ...